Sarah Hogan represents companies in the life sciences and digital health industries on structuring and negotiating intellectual property licenses, strategic collaborations and other complex commercial transactions – helping her clients leverage intellectual property assets and collaborate to develop and deliver innovative solutions that improve health and health care. Sarah uses her science background and comprehensive life sciences industry knowledge as an asset to understand critical business concerns and effectively manage complex issues. As a result of the diverse range of clients and transactions she manages, Sarah has in-depth understanding of the implications of each deal on various aspects of the business, including downstream transactions. Sarah is known for her practical approach – focusing on achieving business objectives while balancing legal risks and preserving her clients’ relationship with their partners.
Sarah regularly advises clients on the following transactions: license and collaboration transactions to develop and commercialize pharmaceutical and medical device products; cross-industry collaborations, joint development arrangements and joint ventures for products in the convergence of health, technology and life sciences; licensing patents, software and other technology from universities; licensing data products and data analytics solutions involving health information; licensing health IT products for both on premise and hosted (including cloud-based) solutions, including hosting, support and maintenance agreements; and manufacturing, supply and distribution agreements relating to pharmaceutical products at all stages of the product life cycle. She represents numerous types of clients, including start-up companies, venture capital and private equity-backed entities, large public companies, privately held businesses, hospitals and nonprofit research institutions.
Represented Baxalta in its global collaboration with Precision BioSciences to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers – a transaction that involved an upfront payment of $105 million from Baxalta, with additional cash payments totaling up to $1.6 billion and royalties on sales. This transaction received the LMG Life Sciences 2016 Collaboration Impact Deal of the Year award
Represented Innate Pharma SA in its co-development and commercialization agreement with AstraZeneca to accelerate and broaden the development of Innate Pharma’s proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune – a transaction that involved an initial payment of $250 million, with additional cash payments of up to $1.275 billion and royalties on sales
Represented a digital health company in structuring and negotiating an exclusive license and distribution transaction to deploy the client’s internet of things (IoT) devices and mobile applications for use in connection with a newly developed telemedicine platform
Represented a digital health software company in its collaboration with a multinational technology internet-related products and services company to develop disease management software
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.